Skip to main content

Table 3 Classical prognostic factors and uPA and PAI-1 tumor tissue levels using standard reference cut-off values

From: Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy

Classical prognostic factors

uPA (ng/mg of protein)

PAI-1 (ng/mg of protein)

Values

Categories

Values

Categories

Mean (SD) Median (Range)

Wilcoxon rank sum

≤ 3

>  3

Pearson χ2 test

Mean (SD) Median (Range)

Wilcoxon rank sum

≤ 14

> 14

Pearson χ2 test

Tumor size

  ≤ 20 mm

3.9 (4.3)

2.5 (0.1–18.7)

nsa

21 (51.2%)

13 (32.5%)

nsb

17.7 (14.1)

12.5 (0.0–51.8)

nsa

18 (56.3%)

16 (32.7%)

nsb

 20–30 mm

4.9 (3.8)

4.0 (0.5–15.5)

15 (36.6%)

22 (55.0%)

24.6 (22.9)

17 (7.5–140)

10 (31.3%)

27 (55.1%)

  > 30 mm

4.3 (2.4)

5.1 (0.6–7.1)

4 (9.8%)

5 (12.5%)

24.6 (16.2)

24.5 (6.0–51.0)

3 (9.4%)

6 (12.2%)

 Unknown

1 (2.4%)

 

1 (3.1%)

Tumor grade

 Grade 1

4.1 (3.1)

5.2 (0.2–8.9)

ns

5 (12.2%)

6 (15.0%)

ns

20.4 (15.3)

18.6 (0.9–46.0)

ns

5 (15.6%)

6 (12.2%)

ns

 Grade 2/3

4.4 (4.0)

3 (0.1–18.7)

36 (87.8%)

34 (85.0%)

21.6 (19.5)

16.0 (0.0–140)

27 (84.4%)

43 (87.8%)

Estrogen receptor

  ≥ 50%

4.1 (3.6)

2.9 (0.2–15.5)

ns

20 (48.8%)

18 (45.0%)

ns

21.9 (23.0)

15.3 (0.9–140)

ns

15 (46.9%)

23 (46.9%)

ns

  < 50%

4.6 (5.2)

3.3 (0.1–18.7)

21 (51.2%)

22 (55.0%)

21.1 (14.6)

16.8 (0.0–56.8)

17 (53.1%)

26 (53.1%)

Ki67 index

  < 15%

3.8 (4.0)

1.8 (0.2–13.3)

ns

14 (34.2%)

8 (20.0%)

0.039

17.0 (13.0)

13.8 (0.9–56.8)

0.038

11 (34.4%)

11 (22.5%)

ns

  ≥ 15%

4.8 (3.4)

5.1 (0.5–15.5)

10 (24.4%)

19 (47.5%)

27.5 (25.3)

20.0 (3.0–140)

7 (21.9%)

22 (44.9%)

Unknown

17 (41.5%)

13 (32.5%)

14 (43.8%)

16 (32.7%)

Total

81 (100%)

41 (100%)

40 (100%)

81 (100%)

32 (100%)

49 (100%)

  1. aKruskal Wallis Test; bFisher exact test; ns-not statistically significant